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Acute Myocardial Infarction
877-STEMI-SC or 877-783-6472
Adult Critical Care Intensivists
320-309-8132
Behavioral Health Access Nurse
320-255-5774
Hospitalist Program 320-290-8933
CentraCare Clinic Specialties
Allergy 320-654-3650
Bariatric Medicine 320-240-2828
Cardiology & Cardiac Surgery
320-656-7020
Dermatology 320-229-4924
Endocrinology 320-229-5000
Gastroenterology 320-229-4916
Genetic Services 320-654-3654
Infectious Disease 320-240-2204
Internal Medicine 320-240-2203
or 320-229-4928
Maternal & Fetal Medicine 
320-656-7024
Neonatology 320-255-5781
Nephrology 320-240-2206
Neurology 320-240-2829
Neurosurgery 320-240-2836
Obstetrics & Gynecology
320-654-3630
Oncology/Hematology
320-229-4907
Pediatric Critical Care 320-255-5781
Pediatrics 320-654-3610
Pulmonology 320-240-2207
Radiation Oncology 320-229-4901
Rheumatology 320-240-2208
Sleep Medicine 320-251-0726
Sports Medicine 320-229-4917
Surgery 320-252-3342
Wound Care 320-656-7100
Physician Referral Line
320-240-2201 
800-458-7272
St. Cloud Hospital
Patient Transfer Line 
(888) 387-2862
A publication from CentraCare Clinic 
for health care providers in Central Minnesota
Population health is the new trend in health care these days.
Unfortunately, there is a lot of confusion about what it means
and how it will influence health care.
‘Population health’ is using data to focus on the delivery of necessary
care to a specific patient population. For example, payers are interested
in the insured population. A provider may be interested in his or her
patients with a particular disease like diabetics or CHF. Employers 
might be interested in their employed population. Public health might 
be interested in a particular geographic area. By analyzing and using
available population data, we can target resources for areas that need 
it rather than using a best-guess approach. 
For example, instead of targeting all of our diabetic patients to improve
care, data analysis reveals that most of our patients are receiving great
care, but diabetics who speak Spanish in a particular community have
persistently elevated LDL values. A Spanish-speaking diabetic educator
could be put into that clinic/community to educate the population and
determine if there are other needs. In this example, a targeted approach
was used that solves problems without excessive use of scarce resources. 
Population health does require that all providers are working together
toward common goals that are well defined and thought out. Ideally,
community resources are identified and used as much as possible and
care is coordinated to the maximum extent possible. Patients could be
engaged to encourage responsibility for their own health. The goal of
population health is to deliver the best care possible and keep people
President’s Message
Population health is a way
of delivering care
By David Tilstra, MD 
President, CentraCare Clinic
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BRCA1 and BRCA2, the first and second hereditary breast
cancer genes, were discovered in 1990 and 1994, respectively.
Since their discovery, more than one million patients have had
BRCA analysis through Myriad Laboratories. Many more have
been tested through other commercial laboratories and through 
research. Recognizing individuals with BRCA alterations
and hereditary cancers is critical to ensure appropriate
medical management for these individuals and their families. 
The National Comprehensive Cancer Network recommends
BRCA analysis for women diagnosed with breast cancer
before age 45 and women with epithelial ovarian cancer at
any age (regardless of family history), women with triple
negative breast cancers (ER/PR/her2neu negative) before
age 60, women with breast cancer and significant family
histories, men with breast cancer, 
and for unaffected individuals who 
have significant family histories. 
(See NCCN Guidelines Genetic/
Familial High Risk Assessment: 
Breast and Ovarian Version 
4.2013) When BRCA testing is 
negative (meaning no alteration 
is found) additional genetic testing 
is recommended, especially if there 
is early onset breast cancer or a 
striking family history.
Not all breast cancer families are 
linked to BRCA1 and BRCA2. 
Other inherited forms of breast 
cancer include Cowden syndrome, 
Li-Fraumeni syndrome, Peutz-Jeghers
syndrome and Hereditary Diffuse Gastric Cancer (which
often is associated with lobular breast cancer) and result
from alterations in the PTEN, p53, STK11 and CDH1
genes, respectively. 
Another 15 to 20 percent of breast cancer cases are believed
to be familial (or a result of a family clustering). Females in
these families are at moderate risk for breast cancer. These
family clusters likely result from alterations in moderate
risk gene(s). Several moderate risk breast
cancer genes have been identified including
PALB2, ATM, NBN, RAD51C, CHEK2,
BARD1 and BRIP1.  
For more than 30 years, Sanger sequencing
was practically the only sequencing method used for BRCA
analysis. This labor-intensive process is expensive and has
slow turnaround times. When additional testing is required,
the costs and time of results rise dramatically.
The demand for cheaper and faster sequencing methods
began in 2005, but only recently has become available
clinically on a widespread basis. Known as Next Generation
Sequencing (NGS), this new method can sequence an entire
genome in less than a day.
This has led to the development 
of NGS Cancer Panels. Some
examples include BRCAplus 
which analyzes the six most
common hereditary breast cancer
genes and MyRisk 25 which
analyzes 17 genes associated with
known hereditary cancer
syndromes and eight modifiers
genes that are associated with
familial clustering of breast and/or
ovarian cancer. These tests can be
offered at pricing comparable to 
or less than BRCA analysis using
Sanger sequencing. 
A variety of NGS Cancer Panels are available commercially
at this time and this field is evolving rapidly. There are site
specific panels for breast, ovarian, colon, pancreatic, and
renal cancers. There are general panels that test for 25 to 250
genes known to be associated with cancer.  
The interpretation of genetic testing for cancer susceptibility
always has been complex. With the inclusion of additional
genes in the analysis, the interpretation can be especially
challenging, particularly when variants of uncertain
significance are found.  The results must be interpreted 
in context of the personal and family history. 
Genetic testing (by specific gene(s) and cancer panels) 
for cancer susceptibility is offered through CentraCare’s
Familial Cancer Clinic to appropriate individuals with
personal and/or significant family history of cancer. 
If you are interested in learning more about this testing 
or have patients who are interested in testing, please 
contact our Genetics Clinic at 320-654-3654.
BRCA1, BRCA2 and Beyond
By Joy Gustin, MS, Certified Genetic Counselor, CentraCare Clinic
Approximately 5 to 10 percent of breast
cancer cases are inherited in families.
Hallmarks of hereditary cancers include: 
• Cancer in two or more close relatives 
on the same side of the family
• Early age at cancer diagnosis (<50)
• Triple negative (ER/PR/her2neu -) 
breast cancer
• Ovarian cancer at any age
• Multiple primary cancers in one 
individual
• Bilateral cancers
• Rare cancers like male breast cancer
• Ashkenazi Jewish descent
President’s Message 
healthy. It’s a great goal that really wasn’t possible 
before data was readily available. It’s also a new way of
delivering care that requires us to rethink how we interact
with patients. Traditional patient care isn’t going away,
but by using population health methods, more effective
care will allow us to thoughtfully deliver the right care 
to the right patient at the right time.
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Introducing our new CentraCare Clinic Specialist
Radiation Oncology     Coborn Cancer Center, 320-229-4901
Daniel J. Ferraro, MD, PhD
Medical School: University of Iowa Carver College of Medicine, Iowa City
Residency: Washington University, St. Louis, Mo.
Board Eligible: Radiation Oncology
Clinical Interests: Head and Neck Cancers, Lung Cancers, CNS tumors, Stereotactic 
Body Radiotherapy, Image Guided Radiotherapy, Intensity Modulated Radiotherapy, 
Stereotactic Radio Surgery
Access all CentraCare Clinic physician bios online at centracare.com
Hyperbaric Oxygen Therapy can help heal wounds
By Denise Larson, DO, Medical Director, and Mike Fuecker, Director,  
CentraCare Wound Center
Hyperbaric Oxygen Therapy (HBOT) helps the body’s
oxygen-dependent, wound-healing mechanisms function
more efficiently. While enclosed in a chamber at greater-
than-normal atmospheric pressure, patients breathe pure
oxygen, saturating their blood plasma and allowing it to
carry 15 to 20 times the normal amount of healing oxygen
to the body’s tissues. 
HBOT also maintains oxygen delivery while blood flow 
is improved in the microcirculation by the edema-reducing
effect of vasoconstriction. 
Approved indications for HBOT provided by the
CentraCare Wound Center and reimbursed by Medicare,
HMOS and other insurance providers include: 
• Diabetic wounds of the lower extremities that meet 
the following three criteria:
- Patient has type I or type II diabetes and has 
a lower extremity wound due to diabetes
- Patient has a wound classified as 
a Wagner III or higher
- Patient has failed an adequate course 
of standard wound therapy
• Arterial insufficiency as an adjunct to 
revascularization
• Chronic refractory osteomyelitis unresponsive 
to conventional medical and surgical management
• Radiation injury (soft tissue, cystitis, proctitis, enteritis 
and osteonecrosis), both treatment of established 
disease and prevention and surgical support
• Skin graphs and flaps, post-operative support 
(limited to outpatient)
• Preparation of compromised or failed recipient site 
for new graft or flap
To learn more about HBOT services or for a patient 
referral, call 320-656-7100 (St. Cloud) or 763-271-2846 
(Monticello). 
CentraCare Clinic’s Dermatology department recently added
the Fraxel Dual 1550/1927 nm laser. This state-of-the-art
laser refreshes the skin, improves skin tone and texture,
wrinkles, pore size, brown spots, age spots, acne scars and
surgical scars, actinic keratoses (pre-cancers) and melasma. 
Fractionation of the laser light results in a non-ablative
treatment that decreases healing time with minimal
downtime. Microscopic laser light columns penetrate the
skin to help remodel collagen, tightening the areas treated.
Patients are pre-treated with a topical anesthetic for minimal
pain. After the laser treatment, patients experience a mild
sunburn-like reaction with redness and slight swelling
lasting a day or two followed by peeling 
of the treated areas. Most patients are
completely healed in a few days.
The addition of this laser complements other
treatments we offer, such as pulsed dye laser
(for redness, rosacea, hemangiomas, birthmarks);
Gentlelase laser (for brown spots and hair removal); fillers
(Restylane, Perlane, Juvederm, Belotero, Radiesse, and
Voluma) and Botox.
If you have a patient who may be appropriate for any 
of our laser or skin-enhancing procedures, please call
CentraCare Clinic Dermatology at 320-229-4924.
Dual Laser remodels collagen, reduces healing time
By Christina Anderson, MD, FAAD, Dermatologist, CentraCare Clinic
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Medicare changes coverage for routine pre-operative 
screening services
By Connie Goulet, CPC; Lindsey Theisen, RHIT; Sue Stein, CPC; and Jessica Timmer, CPC, 
Compliance Specialists, CentraCare Clinic
Effective Sept. 7, 2013, National Government Services 
(the Medicare contractor for Minnesota) no longer reimburses
pre-operative screening services in which the indication is
not clearly documented.
The new policy states:
• The use of diagnostic testing as part of a pre-operative 
examination, where there is an absence of signs or 
symptoms indicating a need for the test, is not covered 
under the Medicare benefit. Such studies will be 
considered not reasonable and medically necessary.
• Routine Pre-operative Screening Codes will no longer 
be covered for the following services: Chest X-ray, EKG, 
Partial Thromboplastin, Prothrombin Time, Serum Iron.
When ordering any of these services, the indication should
be any sign or symptom, chronic disease or if the reason is
clearly a screening, please document this to support the order. 
If the indication is clearly for screening purposes only, 
an ABN must be obtained from the patient.
In addition, National Government Services has updated 
the Removal of Benign Skin Lesions and Trigger Point
Injections policies, please review the links below:
Removal of Benign Skin Lesions:
Go to ngsmedicare.com, select Medical Policy Center link,
in the Search Box type - LCD for Removal of Benign Skin
Lesions (L27362).
Trigger Point Injections:
Go to ngsmedicare.com, select Medical Policy Center link, in
the Search Box type - LCD for Pain Management (L28529).
Within this same search, you also will see a link for additional
instructions to Trigger Point Injections - Article for Pain
Management - Supplemental Instructions Article (A48042).
